Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 50010041
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 700nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.40E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 2.50E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 2.60E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 2.80E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 3.90E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.30E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.30E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.50E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.50E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human CEM cells assessed as inhibition of viral infectionMore data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.60E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.70E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.80E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 4.90E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 6.00E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 6.80E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 6.80E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 7.10E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 7.80E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 8.00E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 8.20E+3nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.20E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.24E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.38E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.50E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 1.50E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based ...More data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 2.50E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human MT4 cells assessed as inhibition of viral infection measured after 16 hrs by cell-based assayMore data for this Ligand-Target Pair
TargetVirion infectivity factor(HIV-1)
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Sanford Burnham Prebys Medical Discovery Institute
Curated by ChEMBL
Affinity DataIC50: 5.00E+4nMAssay Description:Antagonist activity against HIV-1 Vif in human MT4 cells assessed as inhibition of viral infection measured after 16 hrs by cell-based assayMore data for this Ligand-Target Pair








































